Skip to content

Esketamine: all studies

Page 56 of 123: studies 551 to 560 of 1,226, newest first. Back to the esketamine overview

Research

The effects of prophylactic use of esketamine on postoperative depression and quality of life: a meta-analysis.

Minerva anestesiologica April 1, 2024 Guoweng Niu, Xiaozhu Zheng, Bigao Deng et al. 17 citations

The aim of this systemic review and meta-analysis was to assess the impact of prophylactic use of esketamine on postoperative depression and quality of life in patients. We searched for all articles on esketamine in patients after surgury in electronic data bases, including PubMed, EMBASE, Cochrane Central Register of Controlled Trials, Web of Science, up to the June 2023.The included studies...

A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review.

Journal of Affective Disorders April 1, 2024 Sabrina Wong, Angela T H Kwan, Kayla M Teopiz et al. 19 citations

Inadequate outcomes with monoamine-based treatments in depressive disorders are common and provide the impetus for mechanistically-novel treatments. Esketamine is a proven treatment recently approved for adults with Treatment-Resistant Depression (TRD) while psilocybin is an investigational treatment. Translation of the clinical meaningfulness for these foregoing agents in adults with TRD is...

Effects of New Psychoactive Substance Esketamine on Behaviors and Transcription of Genes in Dopamine and GABA Pathways in Zebrafish Larvae.

Bulletin of environmental contamination and toxicology March 31, 2024 Si-Ying Li, Wen-Jun Shi, Dong-Dong Ma et al. 9 citations

Esketamine (ESK) is the S-enantiomer of ketamine racemate (a new psychoactive substance) that can result in illusions, and alter hearing, vision, and proprioception in human and mouse. Up to now, the neurotoxicity caused by ESK at environmental level in fish is still unclear. This work studied the effects of ESK on behaviors and transcriptions of genes in dopamine and GABA pathways in zebrafish...

Perioperative Adjunctive Esketamine for Postpartum Depression Among Women Undergoing Elective Cesarean Delivery

JAMA Network Open March 6, 2024 Yu Chen, Yu Guo, Han Wu et al. 63 citations

Importance Postpartum depression (PPD) is one of the most common mental health conditions during the perinatal and postpartum periods, which can have adverse effects on both mother and infant. Objective To investigate the efficacy of perioperative adjunctive esketamine administration after cesarean deliveries in the prevention of PPD. Design, Setting, and Participants A single-center,...

DOI: 10.1001/jamanetworkopen.2024.0953 (opens in new tab) Full text (opens in new tab) Postpartum-depression Cesarean-section Mental-health Maternal-health +1

Formulary Coverage of Esketamine and Ketamine for Depression in Ohio Health Insurance Marketplace and Medicaid Plans.

Journal of Psychiatric Practice March 1, 2024 Brian S. Barnett 5 citations

For more than 2 decades, intravenous ketamine has been demonstrated to have rapid antidepressant effects. However, access to this generic drug is limited due to insurers claiming it is "experimental" because ketamine does not have a Food and Drug Administration indication for depression. In contrast, intranasal esketamine, an enantiomer of ketamine, is approved by the Food and Drug...

DOI: 10.1097/PRA.0000000000000766 (opens in new tab) Full text (opens in new tab) Ketamine therapy Mental health insurance Depression treatment Healthcare coverage +1

Efficacy of esketamine for the treatment of postpartum depression and pain control following cesarean section: a randomized, double-blind, controlled clinical trial

BMC Anesthesiology February 6, 2024 Shurong Li, Zhifang Zhuo, Renwei Li et al.

Background Postpartum depression (PPD) following a cesarean delivery is a frequently seen complication. Despite the prophylactic effects of ketamine, the impact of esketamine on PPD in women undergoing cesarean section remains uncertain. This study aimed to assess the effectiveness of esketamine as an adjunct to patient-controlled intravenous analgesia (PCIA) in preventing PPD in women...

Efficacy and safety of ketamine and esketamine for unipolar and bipolar depression: an overview of systematic reviews with meta-analysis

Frontiers in Psychiatry February 1, 2024 Alessandro Rodolico, Pierfelice Cutrufelli, Antonio Di Francesco et al. 28 citations

Background Unipolar and bipolar depression present treatment challenges, with patients sometimes showing limited or no response to standard medications. Ketamine and its enantiomer, esketamine, offer promising alternative treatments that can quickly relieve suicidal thoughts. This Overview of Reviews (OoR) analyzed and synthesized systematic reviews (SRs) with meta-analysis on randomized...

Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review.

Cureus February 1, 2024 Suneeta Kumari, Hassan A Chaudhry, Adam Sagot et al. 13 citations

The expansive spectrum of major depressive disorder (MDD) continues to pose challenges for psychiatrists to treat effectively. Oral antidepressant (OAD) medications that alter monoamine neurotransmitters, mainly selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs), have been the mainstay of therapy for decades. Although these drugs have been...

DOI: 10.7759/cureus.53987 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression FDA Approval Nmda receptor antagonist Placebo controlled trials +6

Differed spontaneous dissociative symptoms following the use of esketamine intranasal spray in a patient suffering from treatment-resistant depression: a case report

International Clinical Psychopharmacology January 22, 2024 L. Chevalier, Samuel Bulteau, L. Cheval et al.

Intranasal esketamine is used in France for treatment-resistant depression. Dissociative symptoms are common side effects during treatment sessions. We report a case of delayed spontaneous dissociative symptoms following esketamine administration. A 20-year-old female with treatment-resistant depression received esketamine treatment. Dissociative symptoms occurred during sessions and persisted...